Philip Rowlings

1.4k total citations
26 papers, 778 citations indexed

About

Philip Rowlings is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Philip Rowlings has authored 26 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 9 papers in Genetics and 8 papers in Oncology. Recurrent topics in Philip Rowlings's work include Chronic Lymphocytic Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Philip Rowlings is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Philip Rowlings collaborates with scholars based in Australia, United States and Japan. Philip Rowlings's co-authors include Anoop Enjeti, Carolyn A. Keever-Taylor, Mary M. Horowitz, William H. Burns, David H. Vesole, Greg Bellamy, Yok‐Lam Kwong, S. Thambar, Jakob Passweg and Jane McCrohon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Heart Journal.

In The Last Decade

Philip Rowlings

26 papers receiving 751 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip Rowlings Australia 14 307 229 213 164 158 26 778
Dragomir Marisavljević Serbia 16 307 1.0× 131 0.6× 104 0.5× 117 0.7× 109 0.7× 69 650
Nora Viniou Greece 15 546 1.8× 321 1.4× 157 0.7× 188 1.1× 489 3.1× 43 1.1k
Razelle Kurzrock United States 18 416 1.4× 288 1.3× 90 0.4× 329 2.0× 178 1.1× 24 1.1k
Daniela Belotti Italy 11 461 1.5× 298 1.3× 185 0.9× 27 0.2× 76 0.5× 19 711
Sarah M. Larson United States 14 262 0.9× 200 0.9× 77 0.4× 201 1.2× 343 2.2× 74 749
Jacqueline Vuong United States 8 485 1.6× 331 1.4× 324 1.5× 45 0.3× 104 0.7× 12 1.2k
Seongseok Yun United States 18 344 1.1× 248 1.1× 147 0.7× 206 1.3× 464 2.9× 79 1.1k
Andrey Zaritskey Russia 14 429 1.4× 505 2.2× 143 0.7× 96 0.6× 248 1.6× 66 1.0k
Sophia Jacob United States 7 484 1.6× 341 1.5× 296 1.4× 46 0.3× 66 0.4× 9 1.2k
Maria‐Christina Kyrtsonis Greece 16 445 1.4× 252 1.1× 128 0.6× 200 1.2× 298 1.9× 18 806

Countries citing papers authored by Philip Rowlings

Since Specialization
Citations

This map shows the geographic impact of Philip Rowlings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Rowlings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Rowlings more than expected).

Fields of papers citing papers by Philip Rowlings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Rowlings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Rowlings. The network helps show where Philip Rowlings may publish in the future.

Co-authorship network of co-authors of Philip Rowlings

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Rowlings. A scholar is included among the top collaborators of Philip Rowlings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Rowlings. Philip Rowlings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rowlings, Philip, et al.. (2020). Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab. Journal of NeuroVirology. 26(6). 961–963. 14 indexed citations
2.
Scott, Rodney J., et al.. (2019). Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. Critical Reviews in Oncology/Hematology. 142. 58–67. 21 indexed citations
3.
4.
Dixon‐McIver, Amanda, et al.. (2017). Detection of complex genomic signatures associated with risk in plasma cell disorders. Cancer Genetics. 218-219. 1–9. 7 indexed citations
5.
Saglio, Giuseppe, Philipp le Coutre, Jörge E. Cortes, et al.. (2017). Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology. 96(8). 1303–1313. 13 indexed citations
6.
Enjeti, Anoop, et al.. (2016). A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. Anti-Cancer Drugs. 27(6). 560–568. 16 indexed citations
7.
Enjeti, Anoop, et al.. (2015). A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system. Pathology. 47(6). 570–574. 12 indexed citations
8.
Hall, Alix, Christine Paul, Jamie Bryant, et al.. (2015). To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/Hematology. 97. 247–262. 50 indexed citations
9.
Hong, Sanghee, Christopher A. Barker, John P. Klein, et al.. (2012). Trends in Utilization of Total Body Irradiation (TBI) Prior to Hematopoietic Cell Transplantation (HCT) Worldwide. Biology of Blood and Marrow Transplantation. 18(2). S336–S337. 6 indexed citations
10.
Jordens, Christopher F. C., et al.. (2011). The long haul: Caring for bone marrow transplant patients in regional Australia. Australian journal of advanced nursing. 29(1). 3 indexed citations
11.
Neil, Amanda L., et al.. (2009). Modelling cost‐effectiveness of high‐dose chemotherapy as treatment for relapsed aggressive non‐Hodgkin lymphoma in an Australian setting. Internal Medicine Journal. 39(8). 519–526. 1 indexed citations
12.
Façon, Thierry, Xavier Leleu, A. Keith Stewart, et al.. (2009). Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. Blood. 114(22). 1876–1876. 5 indexed citations
13.
Tse, Hung‐Fat, S. Thambar, Yok‐Lam Kwong, et al.. (2007). Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). European Heart Journal. 28(24). 2998–3005. 121 indexed citations
14.
15.
Tse, Hung‐Fat, S. Thambar, Yok‐Lam Kwong, et al.. (2006). Safety of Catheter-Based Intramyocardial Autologous Bone Marrow Cells Implantation for Therapeutic Angiogenesis. The American Journal of Cardiology. 98(1). 60–62. 35 indexed citations
16.
Sašo, Radovan, J. C. W. Marsh, Lidija Čevreska, et al.. (1999). Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 104(2). 392–396. 92 indexed citations
17.
Juckett, Mark, Philip Rowlings, Martin J. Hessner, et al.. (1998). T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up. Bone Marrow Transplantation. 21(9). 893–899. 47 indexed citations
18.
Burt, Richard K., Ann Traynor, Richard M. Pope, et al.. (1998). Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation. Blood. 92(10). 3505–3514. 17 indexed citations
19.
Kawanishi, Y, Jakob Passweg, William R. Drobyski, et al.. (1997). Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplantation. 19(11). 1069–1077. 41 indexed citations
20.
Sierra, Jorge, Enric Carreras, C Rozmán, et al.. (1997). 192 Bone marrow transplantation for myelodysplasia: The IBMTR data. Leukemia Research. 21(1). S51–S51. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dragomir Marisavljević Breakdown of academic impact, for papers by Nora Viniou Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Daniela Belotti Breakdown of academic impact, for papers by Sarah M. Larson Breakdown of academic impact, for papers by Jacqueline Vuong Breakdown of academic impact, for papers by Seongseok Yun Breakdown of academic impact, for papers by Andrey Zaritskey Breakdown of academic impact, for papers by Sophia Jacob Breakdown of academic impact, for papers by Maria‐Christina Kyrtsonis
Rankless by CCL
2026